Skip to main content
Book cover

Gapmers pp 113–119Cite as

DNA–RNA Heteroduplex Oligonucleotide for Highly Efficient Gene Silencing

Part of the Methods in Molecular Biology book series (MIMB,volume 2176)


Heteroduplex oligonucleotides (HDOs) were a novel type of nucleic acid drugs based on an antisense oligonucleotide (ASO) strand and its complementary RNA (cRNA ) strand. HDOs were originally designed to improve the properties of RNase H-dependent ASOs and we reported in our first paper that HDOs conjugated with an α-tocopherol ligand (Toc-HDO ) based on a gapmer ASO showed 20 times higher silencing effect to liver apolipoprotein B (apoB) mRNA in vivo than the parent ASO. Thereafter the HDO strategy was found to be also effective for improving the properties of ASOs modulating blood–brain barrier function and ASO antimiRs which are RNase H-independent ASOs. Therefore, the HDO strategy has been shown to be versatile technology platform to develop effective nucleic acid drugs.

Key words

  • Nucleic acid drug
  • Heteroduplex oligonucleotide (HDO)
  • Antisense oligonucleotide (ASO)
  • Drug delivery system (DDS)

This is a preview of subscription content, access via your institution.

Buying options

USD   49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
USD   139.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   179.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Springer Nature is developing a new tool to find and evaluate Protocols. Learn more


  1. Kurreck J (2003) Antisense technologies. Eur J Biochem 270:1628–1644

    CrossRef  CAS  Google Scholar 

  2. Seth PP, Swayze EE (2019) The Medicinal Chemistry of RNase H-activating Antisense Oligonucleotides In: Agrawal S, Gait MJ (eds) Advances in nucleic acid therapeutics. RSC publishing, United Kingdom

    Google Scholar 

  3. Wada S, Yasuhara H, Wada F et al (2016) Evaluation of the effects of chemically different linkers on hepatic accumulations, cell tropism and gene silencing ability of cholesterol-conjugated antisense oligonucleotides. J Control Release 226:57–65

    CrossRef  CAS  Google Scholar 

  4. Godard G, Boutorine AS, Saison-Behmoaras E, Hélène C (1995) Antisense effects of cholesterol-Oligodeoxynucleotide conjugates associated with poly(alkylcyanoacrylate) nanoparticles. Eur J Biochem 232:404–410

    CrossRef  CAS  Google Scholar 

  5. Soutschek J, Akinc A, Bramlage B et al (2004) Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432:173

    CrossRef  CAS  Google Scholar 

  6. Lorenz C, Hadwiger P, John M et al (2004) Steroid and lipid conjugates of siRNAs to enhance cellular uptake and gene silencing in liver cells. Bioorg Med Chem Lett 14:4975–4977

    CrossRef  CAS  Google Scholar 

  7. Nishina T, Numata J, Nishina K et al (2015) Chimeric antisense oligonucleotide conjugated to α-Tocopherol. Mol Ther Nucleic Acids 4:e220

    CrossRef  CAS  Google Scholar 

  8. Nishina K, Unno T, Uno Y et al (2008) Efficient in vivo delivery of siRNA to the liver by conjugation of α-Tocopherol. Mol Ther 16:734–740

    CrossRef  CAS  Google Scholar 

  9. Nair JK, Willoughby JL, Chan A et al (2014) Multivalent N-Acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing. J Am Chem Soc 136:16958–16961

    CrossRef  CAS  Google Scholar 

  10. Prakash TP, Graham MJ, Yu J et al (2014) Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice. Nucleic Acids Res 42:8796–8807

    CrossRef  CAS  Google Scholar 

  11. Yu RZ, Graham MJ, Post N et al (2016) Disposition and pharmacology of a GalNAc3-conjugated ASO targeting human lipoprotein (a) in mice. Mol Ther Nucleic Acids 5:e317

    CrossRef  CAS  Google Scholar 

  12. Nishina K, Piao W, Yoshida-Tanaka K et al (2015) DNA/RNA heteroduplex oligonucleotide for highly efficient gene silencing. Nat Commun 6:7969

    CrossRef  CAS  Google Scholar 

  13. Kuwahara H, Song J, Shimoura T et al (2018) Modulation of blood-brain barrier function by a heteroduplex oligonucleotide in vivo. Sci Rep 8:4377

    CrossRef  Google Scholar 

  14. Hogan DJ, Vincent TM, Fish S et al (2014) Anti-miRs competitively inhibit microRNAs in Argonaute complexes. PLoS One 9:e100951

    CrossRef  Google Scholar 

  15. Li Z, Rana TM (2014) Therapeutic targeting of microRNAs: current status and future challenges. Nat Rev Drug Discov 13:622–638

    CrossRef  CAS  Google Scholar 

  16. Yoshioka K, Kunieda T, Asami Y et al (2019) Highly efficient silencing of microRNA by heteroduplex oligonucleotides. Nucleic Acids Res 47(14):7321–7332.

    CrossRef  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Takanori Yokota .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and Permissions

Copyright information

© 2020 Springer Science+Business Media, LLC, part of Springer Nature

About this protocol

Check for updates. Verify currency and authenticity via CrossMark

Cite this protocol

Hara, R.I., Yoshioka, K., Yokota, T. (2020). DNA–RNA Heteroduplex Oligonucleotide for Highly Efficient Gene Silencing. In: Yokota, T., Maruyama, R. (eds) Gapmers. Methods in Molecular Biology, vol 2176. Humana, New York, NY.

Download citation

  • DOI:

  • Published:

  • Publisher Name: Humana, New York, NY

  • Print ISBN: 978-1-0716-0770-1

  • Online ISBN: 978-1-0716-0771-8

  • eBook Packages: Springer Protocols